I agree BB good to clean up the register to meaningful holders and that was the plan announced last year m.
given we have 8 studies underway and 7 with paxalisib as including one phase 3 study underway with so much news coming out this first half of 2021 we are a seriously interesting case for partnership or more.
anyone interested in us or our compounds will not want to wait until we have attained full value and even analysts suggest we have a 35% chance ‘in their view’ of success.
I think we will see a massive rerating this year and over the next two years we will see so much progression in our studies and the completion of GBM Agile.
and I would not be surprised to see double digit SP values that only a couple of years ago would have seemed far fetched... now with the current slate of works underway it seems not only inevitable but a great probability it will be far beyond the lower value double digits for those with the fortitude to hold longer term.
KZA Price at posting:
$1.23 Sentiment: Buy Disclosure: Held
